Block of the lymphocyte K(+) channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single point mutation.
1. Phenylalkylamines (PAA) usually known for their action on L-type Ca(2+) channels potently block the C-type inactivating lymphocyte Kv1.3 channel resulting in inhibition of activation of T lymphocytes. In order to design PAAs blocking Kv1.3 specifically over L-type Ca(2+) channels, we investigated the state-dependent manner of mKv1. 3 block by the PAA verapamil. 2. Verapamil seems to have access to the open state (OB) and, once bound to the channel, the channel-verapamil complex is absorbed into a slowly recovering state. This state was proposed to be the inactivated blocked state (IB). Here we present a quantitative description of the transition into this state and provide evidence for the IB state through experiments with an inactivation lacking mutant channel. Since the inactivated state cannot be reached in this case the IB state cannot be reached either. 3. We show that the transition OB-->IB is accelerated by verapamil most likely through a mechanism involving the reduction of [K(+)] at an inactivation modulating low affinity binding site for K(+) at the outer vestibule. 4. Measurements of the voltage-dependence of the off-rate constants for verapamil suggest that verapamil can reach the channel in its neutral form and might get partially protonated while bound. Thus only those verapamil molecules that are protonated can more easily dissociate at hyperpolarizing voltages. 5. Since open block kinetics were shown to be similar for wild type mKv1.3 and the H404T mutant mKv1.3 channel, and since the block of the H404T mutant channels by verapamil could be described exactly by a simple three-state open block model, the mutant channel could serve as a screening channel to determine open block affinities of new PAA derivatives in high through-put experiments.
Röbe
R J
RJ
Department of Applied Physiology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany.
Grissmer
S
S
D019943:Amino Acid Substitution; D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D007700:Kinetics; D051664:Kv1.3 Potassium Channel; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D008564:Membrane Potentials / Q000187:drug effects; D018408:Patch-Clamp Techniques; D017354:Point Mutation; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000235:genetics / Q000502:physiology; D024642:Potassium Channels, Voltage-Gated; D014407:Tumor Cells, Cultured; D014700:Verapamil / Q000494:pharmacology*
D002121:Calcium Channel Blockers; D051664:Kv1.3 Potassium Channel; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D014700:Verapamil